Acute Lung Injury clinical trials at UC Irvine

• Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia

  Sorry, in progress, not accepting new patients

  This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult patients with Coronavirus Disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute respiratory distress syndrome. Patients will be randomly assigned to receive ravulizumab in addition to best supportive care (BSC) (2/3 of the patients) or BSC alone (1/3 of the patients). Best supportive care will consist of medical treatment and/or medical interventions per routine hospital practice.

  Orange, California and other locations

Last updated: February 2, 2021